• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Lytix Biopharma

Less than 1K followers

LYTIX

Euronext Growth Oslo

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus

Lytix Biopharma is a clinical-stage biotechnology company developing cancer immunotherapies. The company's technology is based on research into antimicrobial peptides, a defense against pathogens. Lytix Biopharma's lead product, LTX-315, is an oncolytic peptide with the aim of personalizing immunotherapy. The company conducts its research and operations in Oslo, Norway.

Read more
Market cap
-
Turnover
-
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
27.8.
2026

Interim report Q2'26

11.11.
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Press release01.06.2026 klo 11.38

DNB Carnegie Access: Lytix Biopharma: Encouraging ASCO presence

Lytix Biopharma
Regulatory press release01.06.2026 klo 08.07

Lytix Biopharma ASA: Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab

Lytix Biopharma
Press release22.05.2026 klo 09.04

DNB Carnegie Access: Lytix Biopharma: Making progress, with data readout on track – Q1 review

Lytix Biopharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release21.05.2026 klo 08.05

Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances

Lytix Biopharma
Regulatory press release15.05.2026 klo 11.23

Lytix Biopharma: Invitation to the Q1 2026 Results Presentation

Lytix Biopharma
Press release06.05.2026 klo 11.53

Redeye: Lytix Biopharma: Abscopal Effects Also in BCC

Lytix Biopharma
Press release06.05.2026 klo 11.01

DNB Carnegie Access: Lytix Biopharma: Complimentary Phase II data to be presented

Lytix Biopharma
Regulatory press release06.05.2026 klo 08.05

Lytix Biopharma ASA: New Phase II Study Data from Lytix Biopharma's Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma

Lytix Biopharma
Press release24.04.2026 klo 10.30

Redeye: Lytix Biopharma (Interview): CEO Øystein Rekdal talks about ATLAS-IT-05

Lytix Biopharma
Regulatory press release21.04.2026 klo 17.05

Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026

Lytix Biopharma
Regulatory press release21.04.2026 klo 08.05

Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma

Lytix Biopharma
Regulatory press release17.04.2026 klo 00.25

Lytix Biopharma ASA - Conversion to public limited liability company and name change registered

Lytix Biopharma
Regulatory press release14.04.2026 klo 18.12

Lytix Biopharma AS: Minutes from Annual General Meeting

Lytix Biopharma
Regulatory press release09.04.2026 klo 21.57

Lytix Biopharma AS: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - GRANT OF SHARE OPTIONS

Lytix Biopharma
Regulatory press release07.04.2026 klo 08.05

Lytix Biopharma AS: Lytix Biopharma Appoints Renée Christine Amundsen as Chief Operating Officer to Support Next Phase of Growth

Lytix Biopharma
Regulatory press release25.03.2026 klo 10.18

Lytix Biopharma AS: Notice of Annual General Meeting on 14 April 2026

Lytix Biopharma
Regulatory press release24.03.2026 klo 08.13

Lytix Biopharma AS: Annual Report for 2025

Lytix Biopharma
Regulatory press release18.03.2026 klo 08.05

Lytix Biopharma AS: Lytix Biopharma to Present Final Phase II ATLAS-IT-05 Data at the AACR Annual Meeting 2026

Lytix Biopharma
Press release09.03.2026 klo 19.11

DNB Carnegie Access: Lytix Biopharma: Maturing pipeline sets up for a pivotal year – initiating coverage

Lytix Biopharma
Regulatory press release24.02.2026 klo 13.23

Lytix Biopharma AS - New share capital registered

Lytix Biopharma